CB conversion price adjusted, dilution reduced
애드바이오텍
179530
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2767
Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Conversion Price: 2,522 KRW/Share (Up from 2,021 KRW/Share)
- • New Convertible Shares: 793,021 Shares (Down from 989,609 Shares)
- • New Dilution Rate: 3.87% (Down from 4.79%)
- • Total Outstanding CBs (including new): 13.25B KRW
- • Total Potential Dilution (all CBs): 35.36% (Down from 36.36%)
AI Analysis Summary
ADBIOTECH Co.,Ltd. has amended its Material Fact Report regarding the issuance of convertible bonds (CBs). The conversion price for the new CBs has been adjusted upwards from 2,021 KRW/Share to 2,522 KRW/Share. This change reduces the number of shares to be issued upon conversion from 989,609 shares to 793,021 shares, consequently lowering the potential dilution rate for the new CBs from 4.79% to 3.87%. The total potential dilution from all outstanding and newly issued CBs is now 35.36% of the current total shares outstanding (19,679,630 shares), a slight improvement from the previous 36.36%. The total value of the newly issued CBs remains 2 billion KRW, with total outstanding CBs at 13.25 billion KRW. The amendment also details early redemption options for bondholders, with redemption rates ranging from 103.00% to 115.08% over the bond's term. While dilution remains a factor, the upward adjustment of the conversion price is a marginally positive development for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.